Interaction between ganciclovir and foscarnet as inhibitors of duck hepatitis B virus replication in vitro.
Safe and effective treatments for chronic hepatitis B virus (HBV) infection have yet to be developed. Both ganciclovir (9-[1,3-dihydroxy-2-propoxymethyl]guanine) and foscarnet (trisodium phosphonoformate hexahydrate) are potent inhibitors of hepadnavirus replication when used individually in vitro and in vivo. However, the clinical usefulness of each drug is reduced by dose-limiting toxicity, especially during long-term monotherapy. Here we demonstrate additive inhibition of duck HBV DNA replication in cultures of primary duck hepatocytes congenitally infected with duck HBV by combinations of ganciclovir and foscarnet at low, clinically achievable concentrations. These results suggest that the effects of ganciclovir and foscarnet against HBV may be additive in vivo.
Civitico
G
G
Victorian Infectious Diseases Reference Laboratory, Fairfield Hospital, Australia.
Shaw
T
T
Locarnini
S
S
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D002478:Cells, Cultured; D004261:DNA Replication / Q000187:drug effects; D004279:DNA, Viral / Q000235:genetics; D004338:Drug Combinations; D004372:Ducks; D017245:Foscarnet / Q000008:administration & dosage / Q000494:pharmacology*; D015774:Ganciclovir / Q000008:administration & dosage / Q000494:pharmacology*; D015611:Hepatitis B Virus, Duck / Q000235:genetics* / Q000502:physiology; D015151:Immunoblotting; D008099:Liver / Q000821:virology; D014758:Viral Core Proteins / Q000096:biosynthesis; D014779:Virus Replication / Q000187:drug effects*
D000998:Antiviral Agents; D004279:DNA, Viral; D004338:Drug Combinations; D014758:Viral Core Proteins; D017245:Foscarnet; D015774:Ganciclovir